Therapeutic strategies in lymphoid malignancies: an immunotherapeutic approach
Gespeichert in:
| Format: | Elektronisch E-Book |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
Oxford
Clinical Pub.
2005
|
| Schlagworte: | |
| Online-Zugang: | FAW01 FAW02 Volltext |
| Beschreibung: | Includes bibliographical references and index Targeted therapies are the focus of much research in oncology. Encouraging results from the development of new monoclonal antibodies are revolutionizing clinical therapies and this is particularly the case for haematologic malignancies. The advent of immunotherapy heralds a new era particularly for patients who are refractory to more traditional therapies. Impressive results are evident using monoclonal antibodies (mAb) that a) bind with high specificity to cell-surface antigens, resulting in targeted killing of the malignant cells or b) are conjugated to radioisotopes, toxins, enzymes or drug |
| Beschreibung: | 1 Online-Ressource (ix, 236 pages) |
| ISBN: | 1846925568 9781846925566 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV043095425 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 151126s2005 |||| o||u| ||||||eng d | ||
| 020 | |a 1846925568 |c electronic bk. |9 1-84692-556-8 | ||
| 020 | |a 9781846925566 |c electronic bk. |9 978-1-84692-556-6 | ||
| 035 | |a (OCoLC)71683623 | ||
| 035 | |a (DE-599)BVBBV043095425 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-1046 |a DE-1047 | ||
| 082 | 0 | |a 616.99/446 |2 22 | |
| 245 | 1 | 0 | |a Therapeutic strategies in lymphoid malignancies |b an immunotherapeutic approach |c edited by Peter Hillmen, Thomas E. Witzig |
| 264 | 1 | |a Oxford |b Clinical Pub. |c 2005 | |
| 300 | |a 1 Online-Ressource (ix, 236 pages) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 500 | |a Includes bibliographical references and index | ||
| 500 | |a Targeted therapies are the focus of much research in oncology. Encouraging results from the development of new monoclonal antibodies are revolutionizing clinical therapies and this is particularly the case for haematologic malignancies. The advent of immunotherapy heralds a new era particularly for patients who are refractory to more traditional therapies. Impressive results are evident using monoclonal antibodies (mAb) that a) bind with high specificity to cell-surface antigens, resulting in targeted killing of the malignant cells or b) are conjugated to radioisotopes, toxins, enzymes or drug | ||
| 650 | 7 | |a MEDICAL / Oncology |2 bisacsh | |
| 650 | 7 | |a HEALTH & FITNESS / Diseases / Cancer |2 bisacsh | |
| 650 | 7 | |a Cancer / Immunotherapy |2 fast | |
| 650 | 7 | |a Lymphatics / Cancer |2 fast | |
| 650 | 4 | |a Lymphoma / immunology | |
| 650 | 4 | |a Lymphoma / therapy | |
| 650 | 4 | |a Immunotherapy / methods | |
| 650 | 4 | |a Medizin | |
| 650 | 4 | |a Lymphatics |x Cancer | |
| 650 | 4 | |a Cancer |x Immunotherapy | |
| 700 | 1 | |a Hillmen, Peter |e Sonstige |4 oth | |
| 700 | 1 | |a Witzig, Thomas E. |e Sonstige |4 oth | |
| 856 | 4 | 0 | |u http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=162327 |x Aggregator |3 Volltext |
| 912 | |a ZDB-4-EBA | ||
| 999 | |a oai:aleph.bib-bvb.de:BVB01-028519617 | ||
| 966 | e | |u http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=162327 |l FAW01 |p ZDB-4-EBA |q FAW_PDA_EBA |x Aggregator |3 Volltext | |
| 966 | e | |u http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=162327 |l FAW02 |p ZDB-4-EBA |q FAW_PDA_EBA |x Aggregator |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804175500180979712 |
|---|---|
| any_adam_object | |
| building | Verbundindex |
| bvnumber | BV043095425 |
| collection | ZDB-4-EBA |
| ctrlnum | (OCoLC)71683623 (DE-599)BVBBV043095425 |
| dewey-full | 616.99/446 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.99/446 |
| dewey-search | 616.99/446 |
| dewey-sort | 3616.99 3446 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02516nmm a2200481zc 4500</leader><controlfield tag="001">BV043095425</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">151126s2005 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1846925568</subfield><subfield code="c">electronic bk.</subfield><subfield code="9">1-84692-556-8</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781846925566</subfield><subfield code="c">electronic bk.</subfield><subfield code="9">978-1-84692-556-6</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)71683623</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV043095425</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-1046</subfield><subfield code="a">DE-1047</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.99/446</subfield><subfield code="2">22</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Therapeutic strategies in lymphoid malignancies</subfield><subfield code="b">an immunotherapeutic approach</subfield><subfield code="c">edited by Peter Hillmen, Thomas E. Witzig</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Oxford</subfield><subfield code="b">Clinical Pub.</subfield><subfield code="c">2005</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (ix, 236 pages)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references and index</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Targeted therapies are the focus of much research in oncology. Encouraging results from the development of new monoclonal antibodies are revolutionizing clinical therapies and this is particularly the case for haematologic malignancies. The advent of immunotherapy heralds a new era particularly for patients who are refractory to more traditional therapies. Impressive results are evident using monoclonal antibodies (mAb) that a) bind with high specificity to cell-surface antigens, resulting in targeted killing of the malignant cells or b) are conjugated to radioisotopes, toxins, enzymes or drug</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Oncology</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">HEALTH & FITNESS / Diseases / Cancer</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Cancer / Immunotherapy</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Lymphatics / Cancer</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Lymphoma / immunology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Lymphoma / therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Immunotherapy / methods</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Medizin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Lymphatics</subfield><subfield code="x">Cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cancer</subfield><subfield code="x">Immunotherapy</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hillmen, Peter</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Witzig, Thomas E.</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=162327</subfield><subfield code="x">Aggregator</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-EBA</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-028519617</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=162327</subfield><subfield code="l">FAW01</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FAW_PDA_EBA</subfield><subfield code="x">Aggregator</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=162327</subfield><subfield code="l">FAW02</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FAW_PDA_EBA</subfield><subfield code="x">Aggregator</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| id | DE-604.BV043095425 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T07:17:16Z |
| institution | BVB |
| isbn | 1846925568 9781846925566 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-028519617 |
| oclc_num | 71683623 |
| open_access_boolean | |
| owner | DE-1046 DE-1047 |
| owner_facet | DE-1046 DE-1047 |
| physical | 1 Online-Ressource (ix, 236 pages) |
| psigel | ZDB-4-EBA ZDB-4-EBA FAW_PDA_EBA |
| publishDate | 2005 |
| publishDateSearch | 2005 |
| publishDateSort | 2005 |
| publisher | Clinical Pub. |
| record_format | marc |
| spelling | Therapeutic strategies in lymphoid malignancies an immunotherapeutic approach edited by Peter Hillmen, Thomas E. Witzig Oxford Clinical Pub. 2005 1 Online-Ressource (ix, 236 pages) txt rdacontent c rdamedia cr rdacarrier Includes bibliographical references and index Targeted therapies are the focus of much research in oncology. Encouraging results from the development of new monoclonal antibodies are revolutionizing clinical therapies and this is particularly the case for haematologic malignancies. The advent of immunotherapy heralds a new era particularly for patients who are refractory to more traditional therapies. Impressive results are evident using monoclonal antibodies (mAb) that a) bind with high specificity to cell-surface antigens, resulting in targeted killing of the malignant cells or b) are conjugated to radioisotopes, toxins, enzymes or drug MEDICAL / Oncology bisacsh HEALTH & FITNESS / Diseases / Cancer bisacsh Cancer / Immunotherapy fast Lymphatics / Cancer fast Lymphoma / immunology Lymphoma / therapy Immunotherapy / methods Medizin Lymphatics Cancer Cancer Immunotherapy Hillmen, Peter Sonstige oth Witzig, Thomas E. Sonstige oth http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=162327 Aggregator Volltext |
| spellingShingle | Therapeutic strategies in lymphoid malignancies an immunotherapeutic approach MEDICAL / Oncology bisacsh HEALTH & FITNESS / Diseases / Cancer bisacsh Cancer / Immunotherapy fast Lymphatics / Cancer fast Lymphoma / immunology Lymphoma / therapy Immunotherapy / methods Medizin Lymphatics Cancer Cancer Immunotherapy |
| title | Therapeutic strategies in lymphoid malignancies an immunotherapeutic approach |
| title_auth | Therapeutic strategies in lymphoid malignancies an immunotherapeutic approach |
| title_exact_search | Therapeutic strategies in lymphoid malignancies an immunotherapeutic approach |
| title_full | Therapeutic strategies in lymphoid malignancies an immunotherapeutic approach edited by Peter Hillmen, Thomas E. Witzig |
| title_fullStr | Therapeutic strategies in lymphoid malignancies an immunotherapeutic approach edited by Peter Hillmen, Thomas E. Witzig |
| title_full_unstemmed | Therapeutic strategies in lymphoid malignancies an immunotherapeutic approach edited by Peter Hillmen, Thomas E. Witzig |
| title_short | Therapeutic strategies in lymphoid malignancies |
| title_sort | therapeutic strategies in lymphoid malignancies an immunotherapeutic approach |
| title_sub | an immunotherapeutic approach |
| topic | MEDICAL / Oncology bisacsh HEALTH & FITNESS / Diseases / Cancer bisacsh Cancer / Immunotherapy fast Lymphatics / Cancer fast Lymphoma / immunology Lymphoma / therapy Immunotherapy / methods Medizin Lymphatics Cancer Cancer Immunotherapy |
| topic_facet | MEDICAL / Oncology HEALTH & FITNESS / Diseases / Cancer Cancer / Immunotherapy Lymphatics / Cancer Lymphoma / immunology Lymphoma / therapy Immunotherapy / methods Medizin Lymphatics Cancer Cancer Immunotherapy |
| url | http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=162327 |
| work_keys_str_mv | AT hillmenpeter therapeuticstrategiesinlymphoidmalignanciesanimmunotherapeuticapproach AT witzigthomase therapeuticstrategiesinlymphoidmalignanciesanimmunotherapeuticapproach |